Steven K. Libutti, MD, FACS, was named director of Rutgers Cancer Institute of New Jersey and vice chancellor for cancer programs, Rutgers Biomedical and Health Sciences, in January 2017. He also serves as a professor of surgery at Robert Wood Johnson Medical School; an affiliated distinguished professor in genetics, School of Arts and Sciences; and senior vice president, oncology services, RWJBarnabas Health.

One of the nation’s 51 National Cancer Institute-designated Comprehensive Cancer Centers and New Jersey’s only such center, Rutgers Cancer Institute fosters collaborations with the state’s universities, health systems, and pharmaceutical and biotechnology companies to bring breakthrough discoveries to patients. Libutti is also strengthening Rutgers Cancer Institute’s outreach and impact throughout the world and has played an active role in Rutgers’ partnership with the nation of Botswana to address cancer care and prevention.

Libutti’s clinical practice focuses on gastrointestinal malignancies, including cancers of the liver and pancreas. His research focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and on a better understanding of the tumor suppressor genes MEN1 and FILIP1L. Libutti is a leader in regional cancer therapy, the management of neuroendocrine tumors, and tumor targeted gene therapy. He is a past president of the American Association of Endocrine Surgeons, serves as editor-in-chief emeritus of the Springer-Nature journal Cancer Gene Therapy, and holds 11 U.S. patents.